Next 10 |
home / stock / abbv / abbv articles
AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the conf...
The most recent trading session ended with AbbVie (NYSE: ABBV) standing at $169.91, reflecting a +1.05% shift from the previouse trading day's ...
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to ma...
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneousl...
All? Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* t...
Tuesday, AbbVie Inc (NYSE:ABBV) announced it received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (f...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) a...
This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's (NYSE: LLY) Alzheimer's disease drug, donanemab. Pfize...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...